China Medical System: New Drug Application for Vitiligo Indication of Ruxolitinib Phosphate Cream Accepted in China
China Medical System Holdings Limited (the “Company”, together with its subsidiaries, the “Group” or “CMS”) is pleased to announce that on September 24, 2024, the New Drug Application (NDA) for ...
Managed Healthcare Executive9d
Adding a Statin to Light Therapy Significantly Improves Vitiligo Treatment Outcomes
Patients with vitiligo may significantly improve the effectiveness of a commonly used light therapy — by nearly twofold— by ...
Zacks.com on MSN1d
Incyte Gains 12.7% Year to Date: How Should You Play the Stock?
Shares of Incyte INCY have risen 12.7% in the past six months against the industry’s decline of 0.5%. The stock has also ...
Business Wire1d
Multiple Late-Breaking Data Presentations from Incyte’s Dermatology Portfolio will be Featured at the European Academy of Dermatology and Venereology (EADV) 2024 …
Multiple Late-Breaking Data Presentations from Incyte’s Dermatology Portfolio will be Featured at the EADV 2024 Congress ...
China Medical System Holdings Ltd.: New Drug Application for Vitiligo Indication of Ruxolitinib Phosphate Cream Accepted in China
China Medical System Holdings Limited (the "Company", together with its subsidiaries, the "Group" or "CMS") is pleased to announce that on September ...